Comparative efficacy of ofatumumab < em > versus < /em > oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons

CONCLUSION: Complementary ITC methods showed ofatumumab was superior to cladribine, fingolimod, and ozanimod in lowering relapse rates and delaying disability progression among patients with RMS. Our study supports the therapeutic superiority of mAbs over currently available oral DMTs for RMS and the delineation of mAbs as high-efficacy therapies.PMID:38525490 | PMC:PMC10960976 | DOI:10.1177/17562864241239453

Source: Adv Data - March 25, 2024 Category: Epidemiology Authors: Nicholas Riley Christopher Drudge Morag Nelson Anja Haltner Michael Barnett Simon Broadley Helmut Butzkueven Pamela McCombe Anneke Van der Walt Erin O Y Wong Martin Merschhemke Nicholas Adlard Rob Walker Imtiaz A Samjoo Source Type: research